AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15887505 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 20
Study 15887505 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:200,000 epinephrine
Number of subjects: 20
Study 15887505 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 20
Study 12841306 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 120
Study 12841306 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 120
Study 12841306 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Vitamin C and E
Number of subjects: 120
Study 12841306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9732305 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (7000 microg retinol equivalents weekly)
Number of subjects: 29000
Study 9732305 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (7000 microg retinol equivalents weekly)
Number of subjects: 29000
Study 9732305 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A and beta-carotene supplementation
Number of subjects: 29000
Study 9732305 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 29000
Study 7666265 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin intake (mean 83.5 units/kg/day)
Number of subjects: 862
Study 7666265 — intervention group
Group type: COMPARATOR
Intervention: No heparin intake (mean 59.4 units/kg/day)
Number of subjects: 862
Study 2773833 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate nicotine dose (15 micrograms/kg body wt)
Number of subjects: 18
Study 2773833 — intervention group
Group type: EXPERIMENTAL
Intervention: Low nicotine dose (7.5 micrograms/kg body wt)
Number of subjects: 18
Study 2773833 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 micrograms)
Number of subjects: 18
Study 61951 — intervention group
Group type: EXPERIMENTAL
Intervention: Benetazone Spofa (trimethazone) 1000 mg/day
Number of subjects: 0
Study 61951 — intervention group
Group type: COMPARATOR
Intervention: Phenylbutazone 600 mg/day
Number of subjects: 0
Study 61951 — intervention group
Group type: EXPERIMENTAL
Intervention: Benetazone Spofa (trimethazone)
Number of subjects: 0
Study 30027510 — intervention group
Group type: EXPERIMENTAL
Intervention: High tie (HT)
Number of subjects: 331
Study 28392176 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 4 times a day (qid) + 1% prednisolone acetate (PA) every hour while awake (q1hWA)
Number of subjects: 42
Study 28392176 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 4 times a day (qid)
Number of subjects: 42
Study 28392176 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 4 times a day (qid) + 1% prednisolone acetate (PA) every hour while awake (q1hWA) after crossover
Number of subjects: 42
Study 28392176 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 4 times a day (qid) after crossover
Number of subjects: 42
Study 26905330 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by radical surgery (NACT-RS)
Number of subjects: 800
Study 26905330 — intervention group
Group type: COMPARATOR
Intervention: Radical surgery alone (RS)
Number of subjects: 800
Study 24984991 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined calcium and iron (700 mg Ca as calcium carbonate plus 30 mg Fe as ferrous sulfate)
Number of subjects: 195
Study 24984991 — intervention group
Group type: COMPARATOR
Intervention: Iron supplementation alone (30 mg Fe as ferrous sulfate)
Number of subjects: 195
Study 23150095 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct application of fibroblast growth factor (FGF)
Number of subjects: 94
Study 23150095 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor (FGF) via Gelfoam
Number of subjects: 94
Study 23150095 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (observation)
Number of subjects: 94
Study 23150095 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct application of fibroblast growth factor (FGF) and FGF via Gelfoam
Number of subjects: 94
Study 19950575 — intervention group
Group type: EXPERIMENTAL
Intervention: PAS group (aspirin 100 mg, atorvastatin 10 mg, probucol 0.25 g daily)
Number of subjects: 436
Study 19950575 — intervention group
Group type: COMPARATOR
Intervention: Control group (aspirin 100 mg, atorvastatin 10 mg daily)
Number of subjects: 436
Study 17964883 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral wrist and MCP splint
Number of subjects: 61
Study 17964883 — intervention group
Group type: COMPARATOR
Intervention: Wrist cock-up splint
Number of subjects: 61
Study 17964883 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral wrist and MCP splint with exercises
Number of subjects: 61
Study 17964883 — intervention group
Group type: COMPARATOR
Intervention: Wrist cock-up splint with exercises
Number of subjects: 61
Study 14692903 — intervention group
Group type: EXPERIMENTAL
Intervention: PGB, 150 mg/day
Number of subjects: 287
Study 14692903 — intervention group
Group type: EXPERIMENTAL
Intervention: PGB, 600 mg/day
Number of subjects: 287
Study 14692903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 11208823 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 monthly cycles of adjuvant CMF chemotherapy
Number of subjects: 386
Study 11208823 — intervention group
Group type: COMPARATOR
Intervention: No further treatment after radical mastectomy
Number of subjects: 386
Study 11360566 — intervention group
Group type: EXPERIMENTAL
Intervention: Feiyan Mixture (FYM)
Number of subjects: 128
Study 11360566 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics
Number of subjects: 128
Study 8092756 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil infusion
Number of subjects: 0
Study 8092756 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline) infusion
Number of subjects: 0
Study 3382042 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue nail polish
Number of subjects: 14
Study 3382042 — intervention group
Group type: EXPERIMENTAL
Intervention: Green nail polish
Number of subjects: 14
Study 3382042 — intervention group
Group type: EXPERIMENTAL
Intervention: Black nail polish
Number of subjects: 14
Study 3382042 — intervention group
Group type: EXPERIMENTAL
Intervention: Purple nail polish
Number of subjects: 14
Study 3382042 — intervention group
Group type: EXPERIMENTAL
Intervention: Red nail polish
Number of subjects: 14
Study 3382042 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown-red nail polish
Number of subjects: 14
Study 31727768 — intervention group
Group type: EXPERIMENTAL
Intervention: BCL2 alterations
Number of subjects: 499
Study 31727768 — intervention group
Group type: EXPERIMENTAL
Intervention: BCL2 translocations
Number of subjects: 499
Study 31727768 — intervention group
Group type: EXPERIMENTAL
Intervention: BCL2 gene and protein expression levels
Number of subjects: 499
Study 30937560 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative saddle nose deformity observed in patients undergoing septoplasty.
Number of subjects: 2106
Study 30937560 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 2106
Study 30937560 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe caudal septal deviation
Number of subjects: 2106
Study 30937560 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative finding of septal cartilage fracture
Number of subjects: 2106
Study 30937560 — intervention group
Group type: COMPARATOR
Intervention: Control group (216 patients with no intraoperative saddle nose deformity)
Number of subjects: 2106
Study 28633777 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial corticosteroid injection
Number of subjects: 30
Study 28633777 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep corticosteroid injection
Number of subjects: 30
Study 25892354 — intervention group
Group type: EXPERIMENTAL
Intervention: Thai foot massage
Number of subjects: 60
Study 25892354 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 23790815 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing for 20 min over three consecutive days about their deepest thoughts and feelings surrounding an emotional event (n=20)
Number of subjects: 40
Study 23790815 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n=20)
Number of subjects: 40
Study 22039193 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain from birth to 3 months
Number of subjects: 10495
Study 22039193 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain from 3 months to 1 year
Number of subjects: 10495
Study 22039193 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain from 1 to 5 years
Number of subjects: 10495
Study 22039193 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthweight
Number of subjects: 10495
Study 19379121 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH
Number of subjects: 0
Study 17291932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 200
Study 17291932 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diuretics
Number of subjects: 200
Study 16060821 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish and English Neuropsychological Assessment Scales (SENAS)
Number of subjects: 527
Study 12120771 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose Plus and silver amalgam (G2)
Number of subjects: 3
Study 12120771 — intervention group
Group type: COMPARATOR
Intervention: Silver amalgam (G1)
Number of subjects: 3
Study 12120771 — intervention group
Group type: COMPARATOR
Intervention: Silver amalgam (G3)
Number of subjects: 3
Study 9925061 — intervention group
Group type: EXPERIMENTAL
Intervention: n of 1 trials (theophylline therapy)
Number of subjects: 68
Study 9925061 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (theophylline therapy)
Number of subjects: 68
Study 9925061 — intervention group
Group type: EXPERIMENTAL
Intervention: n of 1 trials (theophylline treatment)
Number of subjects: 68
Study 8542870 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin (DG I: bolus 0.1 mg.kg‐1 and continuous infusion 0.06 mg.kg‐1.h‐1)
Number of subjects: 117
Study 8542870 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin (DG II: bolus 0.2 mg.kg‐1.h‐1)
Number of subjects: 117
Study 8542870 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin (DG III: bolus 0.4 mg.kg‐1 with 0.15 mg.kg‐1.h‐1)
Number of subjects: 117
Study 8542870 — intervention group
Group type: COMPARATOR
Intervention: Heparin as an adjunct to streptokinase and aspirin (control group)
Number of subjects: 117
Study 2278545 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 487
Study 2278545 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 487
Study 2278545 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (after 8 hours)
Number of subjects: 487
Study 2278545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study 6263115 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana intoxication
Number of subjects: 0
Study 6263115 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 30537083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan (60 mg once a day)
Number of subjects: 50
Study 30537083 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg once a day)
Number of subjects: 50
Study 30537083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan
Number of subjects: 50
Study 30537083 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 50
Study 28691132 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pure emu oil
Number of subjects: 73
Study 28691132 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 73
Study 25445556 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage radiation therapy (SRT) at 66 Gy to the prostate bed, median 86 days after RP
Number of subjects: 388
Study 25445556 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage radiation therapy (SRT)
Number of subjects: 388
Study 25445556 — intervention group
Group type: COMPARATOR
Intervention: Undetectable PSA after RP (arms A + B)
Number of subjects: 388
Study 23806773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (ZA) 4 mg administered within 28 days pre-HCT and at 3 and 6 months after HCT
Number of subjects: 61
Study 23806773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (ZA)
Number of subjects: 61
Study 23806773 — intervention group
Group type: COMPARATOR
Intervention: Control group (calcium carbonate and vitamin D supplements)
Number of subjects: 61
Study 21465940 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 60
Study 21465940 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery (EC)
Number of subjects: 60
Study 18203681 — intervention group
Group type: EXPERIMENTAL
Intervention: Home safety intervention (standardized health visitor safety consultation and free or low-cost safety equipment fitted in the home)
Number of subjects: 0
Study 18203681 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 16888706 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-optimized fluid management (additional colloid boluses based on Doppler assessment)
Number of subjects: 108
Study 16888706 — intervention group
Group type: COMPARATOR
Intervention: Control group (perioperative fluid at the discretion of the anaesthetist)
Number of subjects: 108
Study 15231038 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbopol 971P
Number of subjects: 0
Study 15231038 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbopol 71G
Number of subjects: 0
Study 15231038 — intervention group
Group type: COMPARATOR
Intervention: Buffered and unbuffered media
Number of subjects: 0
Study 11709314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-saquinavir (400 mg b.i.d.)
Number of subjects: 47
Study 11709314 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir (600 mg b.i.d.)
Number of subjects: 47
Study 9381901 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed retrograde locked intramedullary nailing using the Russell‐Taylor nail
Number of subjects: 100
Study 9381901 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed retrograde locked intramedullary nailing using the Synthes prototype unreamed humeral nail
Number of subjects: 100
Study 9381901 — intervention group
Group type: COMPARATOR
Intervention: Closed retrograde locked intramedullary nailing
Number of subjects: 100
Study 7962373 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG with intra-uterine insemination (IUI)
Number of subjects: 91
Study 7962373 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa/HMG with IUI
Number of subjects: 91
Study 7962373 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG with IUI
Number of subjects: 91
Study 3131251 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg b.i.d. (n = 40)
Number of subjects: 80
Study 3131251 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V 2 g t.i.d. (n = 40)
Number of subjects: 80
Study 29657147 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Abatacept (ABA) 125 mg/wk
Number of subjects: 1385
Study 29657147 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Abatacept (ABA)
Number of subjects: 1385
Study 28511482 — intervention group
Group type: EXPERIMENTAL
Intervention: ketofol (25 mg ketamine plus 25 mg propofol)
Number of subjects: 92
Study 28511482 — intervention group
Group type: COMPARATOR
Intervention: placebo (saline)
Number of subjects: 92
Study 28511482 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine (0.25 mg/kg)
Number of subjects: 92
Study 28511482 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol (0.25 mg/kg)
Number of subjects: 92
Study 25698152 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-lipid diet
Number of subjects: 83
Study 25698152 — intervention group
Group type: COMPARATOR
Intervention: Normal-lipid diet
Number of subjects: 83
Study 23325368 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sumatriptan
Number of subjects: 36
Study 23325368 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sumatriptan
Number of subjects: 36
Study 23325368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 23325368 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (both doses)
Number of subjects: 36
Study 23325368 — intervention group
Group type: EXPERIMENTAL
Intervention: SPST (independent of treatment)
Number of subjects: 36
Study 21654430 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month individual-based lifestyle intervention
Number of subjects: 0
Study 21654430 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 19564474 — intervention group
Group type: EXPERIMENTAL
Intervention: hrIFN-alpha 5,000 units
Number of subjects: 88
Study 19564474 — intervention group
Group type: EXPERIMENTAL
Intervention: hrIFN-alpha 30,000 units
Number of subjects: 88
Study 19564474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 17415320 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein, low-fat diet (HPLF)
Number of subjects: 20
Study 17415320 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate, low-fat diet (HCLF)
Number of subjects: 20
Study 15247339 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum nevirapine
Number of subjects: 1844
Study 15247339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1844
Study 11782035 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratification on the rank of the event
Number of subjects: 1265
Study 11782035 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-stratified approach related to Poisson processes theory
Number of subjects: 1265
Study 9264578 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal FUDR + cisplatin (60 mg/m2 in 500 mL of NS)
Number of subjects: 18
Study 9264578 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal FUDR + carboplatin (AUC of 5)
Number of subjects: 18
Study 9264578 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal FUDR + cisplatin (or both platinums)
Number of subjects: 18
Study 8495682 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral omeprazole 40 mg the evening before surgery
Number of subjects: 60
Study 8495682 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral omeprazole 40 mg 2 h before surgery
Number of subjects: 60
Study 8495682 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent cimetidine 800 mg, 2 h before surgery
Number of subjects: 60
Study 8495682 — intervention group
Group type: COMPARATOR
Intervention: No antacid (control group)
Number of subjects: 60
Study 3076118 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600mg twice daily
Number of subjects: 4081
Study 3076118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4081
Study 29194488 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 142
Study 29194488 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 142
Study 28396179 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance group (60 minutes weekly for 40 weeks)
Number of subjects: 201
Study 28396179 — intervention group
Group type: EXPERIMENTAL
Intervention: Music group (60 minutes weekly for 40 weeks)
Number of subjects: 201
Study 28396179 — intervention group
Group type: COMPARATOR
Intervention: Health education control group
Number of subjects: 201
Study 26568937 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gabapentin 20 mg/kg
Number of subjects: 3
Study 26568937 — intervention group
Group type: COMPARATOR
Intervention: Local bupivacaine 2.5 ml 0.25%
Number of subjects: 3
Study 26568937 — intervention group
Group type: COMPARATOR
Intervention: Intravenous pethidine 1 mg/kg
Number of subjects: 3
Study 24041982 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on interpreting fundus photographs
Number of subjects: 138
Study 24041982 — intervention group
Group type: COMPARATOR
Intervention: Direct ophthalmoscopy on simulators
Number of subjects: 138
Study 24041982 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundus photographs
Number of subjects: 138
Study 24041982 — intervention group
Group type: COMPARATOR
Intervention: Direct ophthalmoscopy on simulators or humans
Number of subjects: 138
Study 21150717 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1 peptide vaccine and gemcitabine (GEM) combination therapy
Number of subjects: 25
Study 18434914 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-directed sedation management (n = 153)
Number of subjects: 312
Study 18434914 — intervention group
Group type: COMPARATOR
Intervention: Usual local clinical practice (control, n = 159)
Number of subjects: 312
Study 16799184 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma gel
Number of subjects: 72
Study 16799184 — intervention group
Group type: COMPARATOR
Intervention: Control (saline gel) dressing
Number of subjects: 72
Study 16799184 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma gel (after adjusting for wound size outliers)
Number of subjects: 72
Study 16799184 — intervention group
Group type: COMPARATOR
Intervention: Control (after adjusting for wound size outliers)
Number of subjects: 72
Study 16799184 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-to-healing
Number of subjects: 72
Study 12457587 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve strain Yakult-fermented soymilk
Number of subjects: 0
Study 11167236 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bacitracin and neomycin
Number of subjects: 47
Study 11167236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 47
Study 11167236 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 47
Study 8901773 — intervention group
Group type: EXPERIMENTAL
Intervention: rPF4 (1.0 mg/kg IV over 2 minutes)
Number of subjects: 81
Study 8901773 — intervention group
Group type: COMPARATOR
Intervention: Protamine (50 mg IV over 10 minutes)
Number of subjects: 81
Study 1798376 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill running
Number of subjects: 10